Dx. #ECG #Cardiology

🏝

🚨#NEW 2025 Focused Update #ESC/#EAS #guidelines on dyslipidaemia management Key changes from the 2019 edition👇 #CardioTwitter #ESC2025 #LipidUpdate #LLT

2025 Focused Update of 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Extreme Risk target - Better use of combination therapy - Use of combination therapy at index point of ACS - manage TGs with Icosapent Ethyl or Volanesorsen (>8.5) #ESCCongress #LipidLowering

Dr. Udell now presenting in the prevention of #HeartFailure after AMI #LancetComission #HFPrevention #ESCCongress #WCCongress 🫀stage B: identifying high risk patients using biomarkers, imaging, and the future may be wearables & AI risk models 🫀Fantastic Four of post MI

European Society of Cardiology Started #ESCCongress with a bang ❗️ I still can’t get over how many potentially practice changing #LBCT are being released here! This was just the first one! My favorite will have to be #DIGITHF and the potential so a drug that is inexpensive to be used with more confidence

DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure #LBCT #ESCCongress #WCCongress 2025 🫀1:1 RCT of Dapa 🆚 Placebo 🫀34% female, 19% Black 🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of

Pharmacotherapy in HFpEF : where do cardiometabolic drugs fit in? Wonderful summary by Harriette Van Spall, MD MPH 🇨🇦 #ESCCongress #Pharmacotherapy

Some great slides from #Guidelines discussion on triglycerides reduction. Check them out. 📉 Not all TG-lowering therapies equal CV benefit. •Statins: ↓TG 15–26% ✅ CV benefit •Fibrates: ↓TG ~26% ❌ no clear CV benefit •High-dose icosapent ethyl (EPA): ↓TG 20% ✅ CV

Dx.

🏞

Dx.

2.

thelancet.com/journals/lance…

3.

Dx.